peripheral arterial disease/protease

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 71 rezilta yo

Protein Z-dependent protease inhibitor and protein Z in peripheral arterial disease patients.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE Protein Z is a vitamin K-dependent protein that serves as a cofactor for the inhibition of activated factor X by the serpin protein Z-dependent protease inhibitor (ZPI). Protein Z plasma levels have been shown to be reduced in patients with peripheral arterial disease (PAD), but ZPI levels

Protease-resistant stromal cell-derived factor-1 for the treatment of experimental peripheral artery disease.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Peripheral artery disease is a potentially incapacitating disease for which pharmacological options are limited. Stromal cell-derived factor-1 (SDF-1) is a chemokine that attracts endothelial progenitor cells and promotes angiogenesis. Therapeutic use of SDF-1 in hindlimb ischemia may be

Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Despite the current standard of care, patients with cardiovascular disease remain at a high risk for recurrent events. Inhibition of thrombin-mediated platelet activation through protease-activated receptor-1 antagonism may provide reductions in atherosclerotic disease beyond those

Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, dosage and administration, cost, and place in therapy of vorapaxar in the secondary prevention of atherosclerotic events are reviewed. CONCLUSIONS Vorapaxar is a highly selective, reversible antagonist of

Protease-Activated Receptor 1 Inhibitors: Novel Antiplatelet Drugs in Prevention of Atherothrombosis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Protease-activated receptor (PAR)-1 inhibitors have recently become popular in the use of atherosclerosis among clinicians. Atherosclerosis can cause cardiovascular and cerebrovascular events leading to one of the major causes of mortality worldwide. Thrombin-mediated platelets can cause

Octahydrocyclopenta[c]pyridine and octahydrocyclopenta[c]pyran analogues as a protease activated receptor 1 (PAR1) antagonist.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Protease activated receptor 1 (PAR1) has been considered as a promising antiplatelet target to prevent thrombotic cardiovascular events in patients with prior myocardial infarction or peripheral arterial diseases. Previously, we found a series of octahydroindene analogues to have high potency on

Approval of the first protease-activated receptor antagonist: Rationale, development, significance, and considerations of a novel anti-platelet agent.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Twenty-three years after the discovery of the first thrombin receptor, now known as protease-activated receptor 1 (PAR1), the first drug targeting this receptor is available for human use. The PAR1 inhibitor, vorapaxar (Zontivity, MSD), was recently approved by the FDA for use in the USA for the

Vorapaxar, a Protease-Activated Receptor-1 Antagonist, a Double-Edged Sword!

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Acute coronary syndrome (ACS) constitutes a group of pathophysiological entities resulting from reduced blood flow in the coronary arteries leading to decreased or improper functioning or death of heart muscle. Such patients are usually prescribed combination antiplatelet drug therapy, containing

Trans-fused 5-[(tert-Butoxtycarbonyl)amino]octahydroindenes as a protease activated receptor-1 (PAR1) antagonist.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Vorapaxar: A Protease-Activated Receptor Antagonist for the Prevention of Thrombotic Events.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Antiplatelet therapy reduces the risks for cardiovascular morbidity and mortality in patients with atherosclerotic disease, and it is also beneficial in managing peripheral arterial disease (PAD). These agents work through various therapeutic pathways to achieve antithrombotic effects. Although

Peripheral artery disease and antiplatelet treatment.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Peripheral artery disease (PAD) is one of the most important causes of cardiovascular morbidity and mortality and its prevalence is alarmingly increasing in modern societies. PAD shares common characteristics with the other atherosclerotic diseases but involves specifically the arteries of the lower

Residual thrombin generation potential is inversely linked to the occurrence of atherothrombotic events in patients with peripheral arterial disease.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND The serine protease thrombin is the most potent platelet agonist and acts mainly via protease-activated receptors (PAR)-1 and -4. Data linking in vitro thrombin generation potential with PAR-1-mediated platelet activation and adverse events after angioplasty and stenting are missing, so

PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Low-density lipoprotein cholesterol (LDL-C) has been proven to be a causal factor of atherosclerosis and, along with other triggers like inflammation, the most frequent reason for peripheral arterial disease. Moreover, a linear correlation between LDL-C concentration and cardiovascular outcome in

Association of the von Willebrand Factor-ADAMTS13 Ratio With Incident Cardiovascular Events in Patients With Peripheral Arterial Disease.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Platelet adhesion is mediated by von Willebrand factor (vWF), and disintegrin-like and metalloprotease domain with thrombospondin type-1 motif, number 13 (ADAMTS13) is a protease that cleaves vWF. A change in the balance between vWF and ADAMTS13 in favor of thrombosis might occur shortly

Protease-activated receptor 4: from structure to function and back again.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Protease-activated receptors are a family of four GPCRs (PAR1-PAR4) with a number of unique attributes. Nearly two and a half decades after the discovery of the first PAR, an antagonist targeting this receptor has been approved for human use. The first-in-class PAR1 antagonist, vorapaxar, was

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye